5KW.F SKINBIO THERAP LS-01
- Market cap
- EUR 9.85M
- P/E
- -
- P/B
- 1.03x
- ROE
- -7.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2025.
Is 5KW.F undervalued?
Graham numberThe Graham number of SKINBIO THERAP LS-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SKINBIO THERAP LS-01 fundamental analysis
No fundamental analysis for SKINBIO THERAP LS-01 yet.
SKINBIO THERAP LS-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SKINBIO THERAP LS-01
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix whic…
Full company profileSKINBIO THERAP LS-01 financial statements
SKINBIO THERAP LS-01 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 74.8K | 132K | 1.21M | 4.64M |
| Gross Profit | 45.3K | 85.2K | 683K | 2.86M |
| Operating Income | -2.71M | -2.96M | -2.95M | -1.12M |
| EBITDA | -2.94M | -2.94M | -2.73M | -197K |
| Net Income | -2.79M | -2.84M | -2.88M | -696K |
| EPS | -0.02 | -0.02 | -0.01 | 0.00 |
| Balance Sheet | ||||
| Total Assets | 3.08M | 2.59M | 5.22M | 12.1M |
| Total Liabilities | 610K | 599K | 2.25M | 2.71M |
| Shareholders' Equity | 2.48M | 1.99M | 2.97M | 9.42M |
| Cash & Short-term Investments | 1.80M | 1.31M | 801K | 4.78M |
| Cash Flow | ||||
| Operating Cash Flow | -2.67M | -2.65M | -2.73M | -1.24M |
| Capital Expenditure | 96.8K | 165K | 198K | 159K |
| Free Cash Flow | -2.77M | -2.81M | -2.92M | -1.39M |
| Ratios | ||||
| ROE | -112.8% | -142.1% | -96.8% | -7.4% |
| ROA | -90.5% | -109.3% | -55.1% | -5.7% |
| Net Profit Margin | -3,735.4% | -2,146.9% | -237.9% | -15.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SKINBIO THERAP LS-01 dividends
SKINBIO THERAP LS-01 has not paid dividends in the last 4 fiscal years.
Who owns SKINBIO THERAP LS-01
- Insiders 41.14%
- Institutions 13.41%
- Public & others 45.46%
- Shares outstanding 259M
- Free float 116M
SKINBIO THERAP LS-01 company profile
- Company name
- SKINBIO THERAP LS-01
- Ticker
- 5KW.F
- ISIN
- GB00BF33H870
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- June
- Address
- Unit 75, Driffield, United Kingdom, YO25 9FQ
- Phone
- 44 19 1495 7325
- Website
- skinbiotherapeutics.com
About SKINBIO THERAP LS-01
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Driffield, the United Kingdom.
SKINBIO THERAP LS-01 management
7- Ms. Rachel Lisa ParsonageCEO & Director · born 1974
- Ms. Anita SlaterInterim Chief Financial Officer
- Ms. Vanessa RyderCustomer Service and Operations Manager
- Ms. Vicky ChristieGroup Marketing Manager
- Mr. Tom WaughmanManaging Director at Dermatonics
- Mr. Tim WakeleyManaging Director at Bio-Tech Solutions
- Ms. Melissa GreenwellGroup Financial Controller